anti src Search Results


94
R&D Systems rabbit anti human phospho src y419 antibody
Rabbit Anti Human Phospho Src Y419 Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit anti human phospho src y419 antibody/product/R&D Systems
Average 94 stars, based on 1 article reviews
rabbit anti human phospho src y419 antibody - by Bioz Stars, 2026-04
94/100 stars
  Buy from Supplier

93
Novus Biologicals phospho p65 nk κb
Phospho P65 Nk κb, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/phospho p65 nk κb/product/Novus Biologicals
Average 93 stars, based on 1 article reviews
phospho p65 nk κb - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier

92
R&D Systems phospho src y418
Phospho Src Y418, supplied by R&D Systems, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/phospho src y418/product/R&D Systems
Average 92 stars, based on 1 article reviews
phospho src y418 - by Bioz Stars, 2026-04
92/100 stars
  Buy from Supplier

90
R&D Systems src antibody
Src Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/src antibody/product/R&D Systems
Average 90 stars, based on 1 article reviews
src antibody - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

93
R&D Systems mouse anti src mab6
(A) Domain structure of human c-Src protein (UniprotKB: P12931) with key regulatory sites illustrated. From the N to the C terminus, domains include the N-term SRC homology SH4 with the U (brown), SH3 (blue), SH2 (orange), KD (SH1; green), and C-term R (red) domains. Domain range is indicated with residue numbers shown below each domain (above for SH3). Regions targeted by the mAbs tested in this study are indicated (black brackets). One asterisk (*) indicates mAbs that inhibit TIMP2 tyrosine phosphorylation and TIMP2 interaction with MMP-2. Two asterisks (**) indicate the <t>mAb6</t> did not block TIMP2 phosphorylation or its interaction with MMP2 in experiments performed in this figure. (B) Schematic representation of sample preparation and processing for evaluating anti-c-Src Abs in cells.</p/>(C and D) SYF+c-Src in (C) or HT1080 in (D) cells were seeded for 18 h, followed by serum starvation for 24 h. Cells were pretreated for 1 h with indicated anti-c-Src Ab or IgG as a control, followed by incubation with recombinant TIMP2-His for 2 h. Cell extracts and CMs were collected and analyzed by western blot and pull-down experiments. (C) SYF+c-Src cells were pretreated with anti-c-Src mAb1 (clone 32G6, biotinylated), mAb2 (clone 327), or IgG isotype control (clone DA1E, biotinylated) or were left untreated. Following incubation with recombinant TIMP2-His 6 (rTIMP2-His 6 ), TIMP2-His 6 was pulled-down from CM using Ni-NTA resin. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 and e-Src was determined by immunoblot. GAPDH (cell extracts) was used as loading control (Lys C). (D) HT1080 cells were pretreated with anti-c-Src mAb6 (clone 327537), mAb5 (clone 32G6), or IgG isotype control (clone 20102) or were left untreated. Following incubation with rTIMP2-His 6 , TIMP2-His 6 was pulled down from CM. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 was determined by immunoblot. (E) Schematic representation c-Src SH4/U and SH3 domains. The critical region used as immunogen for generating the polyclonal Ab (aa 84–110) in this study is highlighted in pink. (F) HT1080 cells were pretreated with anti-c-Src pAb (aa 84–110) or IgG isotype control (clone ERP25A) or were left untreated. Following incubation with rTIMP2-His 6 , TIMP2-His 6 was pulled down from CM. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 was determined by immunoblot. (G) Schematic representation of sample preparation for (H). Prostate cancer cells (LNCaP, DU-145, PC-3) were seeded in a 96-well plate for 18 h, followed by the addition (treatment) of the anti-c-Src Ab or IgG isotype control (clone ERP25A). After 72 h, cell proliferation was measured using a WST assay. (H) Proliferation assay on prostate cancer cells treated with the indicated concentration of antibody or IgG was measured by WST assay. The graph shows the percentage of growth normalized to the untreated sample. Data are presented as mean ± SEM derived from two technical replicates. Data presented are a representative result of 3 independent experiments. Paired two-tailed t test was used to assess statistical significance between IgG treatment and anti-c-Src treatment at 50 μg/mL for each cell line (*p < 0.05, **p < 0.01). SE, short exposure; LE, long exposure. See also .
Mouse Anti Src Mab6, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse anti src mab6/product/R&D Systems
Average 93 stars, based on 1 article reviews
mouse anti src mab6 - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier

90
R&D Systems anti src
(A) Domain structure of human c-Src protein (UniprotKB: P12931) with key regulatory sites illustrated. From the N to the C terminus, domains include the N-term SRC homology SH4 with the U (brown), SH3 (blue), SH2 (orange), KD (SH1; green), and C-term R (red) domains. Domain range is indicated with residue numbers shown below each domain (above for SH3). Regions targeted by the mAbs tested in this study are indicated (black brackets). One asterisk (*) indicates mAbs that inhibit TIMP2 tyrosine phosphorylation and TIMP2 interaction with MMP-2. Two asterisks (**) indicate the <t>mAb6</t> did not block TIMP2 phosphorylation or its interaction with MMP2 in experiments performed in this figure. (B) Schematic representation of sample preparation and processing for evaluating anti-c-Src Abs in cells.</p/>(C and D) SYF+c-Src in (C) or HT1080 in (D) cells were seeded for 18 h, followed by serum starvation for 24 h. Cells were pretreated for 1 h with indicated anti-c-Src Ab or IgG as a control, followed by incubation with recombinant TIMP2-His for 2 h. Cell extracts and CMs were collected and analyzed by western blot and pull-down experiments. (C) SYF+c-Src cells were pretreated with anti-c-Src mAb1 (clone 32G6, biotinylated), mAb2 (clone 327), or IgG isotype control (clone DA1E, biotinylated) or were left untreated. Following incubation with recombinant TIMP2-His 6 (rTIMP2-His 6 ), TIMP2-His 6 was pulled-down from CM using Ni-NTA resin. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 and e-Src was determined by immunoblot. GAPDH (cell extracts) was used as loading control (Lys C). (D) HT1080 cells were pretreated with anti-c-Src mAb6 (clone 327537), mAb5 (clone 32G6), or IgG isotype control (clone 20102) or were left untreated. Following incubation with rTIMP2-His 6 , TIMP2-His 6 was pulled down from CM. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 was determined by immunoblot. (E) Schematic representation c-Src SH4/U and SH3 domains. The critical region used as immunogen for generating the polyclonal Ab (aa 84–110) in this study is highlighted in pink. (F) HT1080 cells were pretreated with anti-c-Src pAb (aa 84–110) or IgG isotype control (clone ERP25A) or were left untreated. Following incubation with rTIMP2-His 6 , TIMP2-His 6 was pulled down from CM. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 was determined by immunoblot. (G) Schematic representation of sample preparation for (H). Prostate cancer cells (LNCaP, DU-145, PC-3) were seeded in a 96-well plate for 18 h, followed by the addition (treatment) of the anti-c-Src Ab or IgG isotype control (clone ERP25A). After 72 h, cell proliferation was measured using a WST assay. (H) Proliferation assay on prostate cancer cells treated with the indicated concentration of antibody or IgG was measured by WST assay. The graph shows the percentage of growth normalized to the untreated sample. Data are presented as mean ± SEM derived from two technical replicates. Data presented are a representative result of 3 independent experiments. Paired two-tailed t test was used to assess statistical significance between IgG treatment and anti-c-Src treatment at 50 μg/mL for each cell line (*p < 0.05, **p < 0.01). SE, short exposure; LE, long exposure. See also .
Anti Src, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti src/product/R&D Systems
Average 90 stars, based on 1 article reviews
anti src - by Bioz Stars, 2026-04
90/100 stars
  Buy from Supplier

93
R&D Systems c src kinase
(A) Domain structure of human c-Src protein (UniprotKB: P12931) with key regulatory sites illustrated. From the N to the C terminus, domains include the N-term SRC homology SH4 with the U (brown), SH3 (blue), SH2 (orange), KD (SH1; green), and C-term R (red) domains. Domain range is indicated with residue numbers shown below each domain (above for SH3). Regions targeted by the mAbs tested in this study are indicated (black brackets). One asterisk (*) indicates mAbs that inhibit TIMP2 tyrosine phosphorylation and TIMP2 interaction with MMP-2. Two asterisks (**) indicate the <t>mAb6</t> did not block TIMP2 phosphorylation or its interaction with MMP2 in experiments performed in this figure. (B) Schematic representation of sample preparation and processing for evaluating anti-c-Src Abs in cells.</p/>(C and D) SYF+c-Src in (C) or HT1080 in (D) cells were seeded for 18 h, followed by serum starvation for 24 h. Cells were pretreated for 1 h with indicated anti-c-Src Ab or IgG as a control, followed by incubation with recombinant TIMP2-His for 2 h. Cell extracts and CMs were collected and analyzed by western blot and pull-down experiments. (C) SYF+c-Src cells were pretreated with anti-c-Src mAb1 (clone 32G6, biotinylated), mAb2 (clone 327), or IgG isotype control (clone DA1E, biotinylated) or were left untreated. Following incubation with recombinant TIMP2-His 6 (rTIMP2-His 6 ), TIMP2-His 6 was pulled-down from CM using Ni-NTA resin. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 and e-Src was determined by immunoblot. GAPDH (cell extracts) was used as loading control (Lys C). (D) HT1080 cells were pretreated with anti-c-Src mAb6 (clone 327537), mAb5 (clone 32G6), or IgG isotype control (clone 20102) or were left untreated. Following incubation with rTIMP2-His 6 , TIMP2-His 6 was pulled down from CM. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 was determined by immunoblot. (E) Schematic representation c-Src SH4/U and SH3 domains. The critical region used as immunogen for generating the polyclonal Ab (aa 84–110) in this study is highlighted in pink. (F) HT1080 cells were pretreated with anti-c-Src pAb (aa 84–110) or IgG isotype control (clone ERP25A) or were left untreated. Following incubation with rTIMP2-His 6 , TIMP2-His 6 was pulled down from CM. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 was determined by immunoblot. (G) Schematic representation of sample preparation for (H). Prostate cancer cells (LNCaP, DU-145, PC-3) were seeded in a 96-well plate for 18 h, followed by the addition (treatment) of the anti-c-Src Ab or IgG isotype control (clone ERP25A). After 72 h, cell proliferation was measured using a WST assay. (H) Proliferation assay on prostate cancer cells treated with the indicated concentration of antibody or IgG was measured by WST assay. The graph shows the percentage of growth normalized to the untreated sample. Data are presented as mean ± SEM derived from two technical replicates. Data presented are a representative result of 3 independent experiments. Paired two-tailed t test was used to assess statistical significance between IgG treatment and anti-c-Src treatment at 50 μg/mL for each cell line (*p < 0.05, **p < 0.01). SE, short exposure; LE, long exposure. See also .
C Src Kinase, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/c src kinase/product/R&D Systems
Average 93 stars, based on 1 article reviews
c src kinase - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier

97
Santa Cruz Biotechnology c src
(A) Domain structure of human c-Src protein (UniprotKB: P12931) with key regulatory sites illustrated. From the N to the C terminus, domains include the N-term SRC homology SH4 with the U (brown), SH3 (blue), SH2 (orange), KD (SH1; green), and C-term R (red) domains. Domain range is indicated with residue numbers shown below each domain (above for SH3). Regions targeted by the mAbs tested in this study are indicated (black brackets). One asterisk (*) indicates mAbs that inhibit TIMP2 tyrosine phosphorylation and TIMP2 interaction with MMP-2. Two asterisks (**) indicate the <t>mAb6</t> did not block TIMP2 phosphorylation or its interaction with MMP2 in experiments performed in this figure. (B) Schematic representation of sample preparation and processing for evaluating anti-c-Src Abs in cells.</p/>(C and D) SYF+c-Src in (C) or HT1080 in (D) cells were seeded for 18 h, followed by serum starvation for 24 h. Cells were pretreated for 1 h with indicated anti-c-Src Ab or IgG as a control, followed by incubation with recombinant TIMP2-His for 2 h. Cell extracts and CMs were collected and analyzed by western blot and pull-down experiments. (C) SYF+c-Src cells were pretreated with anti-c-Src mAb1 (clone 32G6, biotinylated), mAb2 (clone 327), or IgG isotype control (clone DA1E, biotinylated) or were left untreated. Following incubation with recombinant TIMP2-His 6 (rTIMP2-His 6 ), TIMP2-His 6 was pulled-down from CM using Ni-NTA resin. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 and e-Src was determined by immunoblot. GAPDH (cell extracts) was used as loading control (Lys C). (D) HT1080 cells were pretreated with anti-c-Src mAb6 (clone 327537), mAb5 (clone 32G6), or IgG isotype control (clone 20102) or were left untreated. Following incubation with rTIMP2-His 6 , TIMP2-His 6 was pulled down from CM. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 was determined by immunoblot. (E) Schematic representation c-Src SH4/U and SH3 domains. The critical region used as immunogen for generating the polyclonal Ab (aa 84–110) in this study is highlighted in pink. (F) HT1080 cells were pretreated with anti-c-Src pAb (aa 84–110) or IgG isotype control (clone ERP25A) or were left untreated. Following incubation with rTIMP2-His 6 , TIMP2-His 6 was pulled down from CM. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 was determined by immunoblot. (G) Schematic representation of sample preparation for (H). Prostate cancer cells (LNCaP, DU-145, PC-3) were seeded in a 96-well plate for 18 h, followed by the addition (treatment) of the anti-c-Src Ab or IgG isotype control (clone ERP25A). After 72 h, cell proliferation was measured using a WST assay. (H) Proliferation assay on prostate cancer cells treated with the indicated concentration of antibody or IgG was measured by WST assay. The graph shows the percentage of growth normalized to the untreated sample. Data are presented as mean ± SEM derived from two technical replicates. Data presented are a representative result of 3 independent experiments. Paired two-tailed t test was used to assess statistical significance between IgG treatment and anti-c-Src treatment at 50 μg/mL for each cell line (*p < 0.05, **p < 0.01). SE, short exposure; LE, long exposure. See also .
C Src, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/c src/product/Santa Cruz Biotechnology
Average 97 stars, based on 1 article reviews
c src - by Bioz Stars, 2026-04
97/100 stars
  Buy from Supplier

96
Cell Signaling Technology Inc polyclonal anti phosphosrc
(A) Domain structure of human c-Src protein (UniprotKB: P12931) with key regulatory sites illustrated. From the N to the C terminus, domains include the N-term SRC homology SH4 with the U (brown), SH3 (blue), SH2 (orange), KD (SH1; green), and C-term R (red) domains. Domain range is indicated with residue numbers shown below each domain (above for SH3). Regions targeted by the mAbs tested in this study are indicated (black brackets). One asterisk (*) indicates mAbs that inhibit TIMP2 tyrosine phosphorylation and TIMP2 interaction with MMP-2. Two asterisks (**) indicate the <t>mAb6</t> did not block TIMP2 phosphorylation or its interaction with MMP2 in experiments performed in this figure. (B) Schematic representation of sample preparation and processing for evaluating anti-c-Src Abs in cells.</p/>(C and D) SYF+c-Src in (C) or HT1080 in (D) cells were seeded for 18 h, followed by serum starvation for 24 h. Cells were pretreated for 1 h with indicated anti-c-Src Ab or IgG as a control, followed by incubation with recombinant TIMP2-His for 2 h. Cell extracts and CMs were collected and analyzed by western blot and pull-down experiments. (C) SYF+c-Src cells were pretreated with anti-c-Src mAb1 (clone 32G6, biotinylated), mAb2 (clone 327), or IgG isotype control (clone DA1E, biotinylated) or were left untreated. Following incubation with recombinant TIMP2-His 6 (rTIMP2-His 6 ), TIMP2-His 6 was pulled-down from CM using Ni-NTA resin. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 and e-Src was determined by immunoblot. GAPDH (cell extracts) was used as loading control (Lys C). (D) HT1080 cells were pretreated with anti-c-Src mAb6 (clone 327537), mAb5 (clone 32G6), or IgG isotype control (clone 20102) or were left untreated. Following incubation with rTIMP2-His 6 , TIMP2-His 6 was pulled down from CM. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 was determined by immunoblot. (E) Schematic representation c-Src SH4/U and SH3 domains. The critical region used as immunogen for generating the polyclonal Ab (aa 84–110) in this study is highlighted in pink. (F) HT1080 cells were pretreated with anti-c-Src pAb (aa 84–110) or IgG isotype control (clone ERP25A) or were left untreated. Following incubation with rTIMP2-His 6 , TIMP2-His 6 was pulled down from CM. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 was determined by immunoblot. (G) Schematic representation of sample preparation for (H). Prostate cancer cells (LNCaP, DU-145, PC-3) were seeded in a 96-well plate for 18 h, followed by the addition (treatment) of the anti-c-Src Ab or IgG isotype control (clone ERP25A). After 72 h, cell proliferation was measured using a WST assay. (H) Proliferation assay on prostate cancer cells treated with the indicated concentration of antibody or IgG was measured by WST assay. The graph shows the percentage of growth normalized to the untreated sample. Data are presented as mean ± SEM derived from two technical replicates. Data presented are a representative result of 3 independent experiments. Paired two-tailed t test was used to assess statistical significance between IgG treatment and anti-c-Src treatment at 50 μg/mL for each cell line (*p < 0.05, **p < 0.01). SE, short exposure; LE, long exposure. See also .
Polyclonal Anti Phosphosrc, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/polyclonal anti phosphosrc/product/Cell Signaling Technology Inc
Average 96 stars, based on 1 article reviews
polyclonal anti phosphosrc - by Bioz Stars, 2026-04
96/100 stars
  Buy from Supplier

96
Cell Signaling Technology Inc rabbit anti src
(A) Domain structure of human c-Src protein (UniprotKB: P12931) with key regulatory sites illustrated. From the N to the C terminus, domains include the N-term SRC homology SH4 with the U (brown), SH3 (blue), SH2 (orange), KD (SH1; green), and C-term R (red) domains. Domain range is indicated with residue numbers shown below each domain (above for SH3). Regions targeted by the mAbs tested in this study are indicated (black brackets). One asterisk (*) indicates mAbs that inhibit TIMP2 tyrosine phosphorylation and TIMP2 interaction with MMP-2. Two asterisks (**) indicate the <t>mAb6</t> did not block TIMP2 phosphorylation or its interaction with MMP2 in experiments performed in this figure. (B) Schematic representation of sample preparation and processing for evaluating anti-c-Src Abs in cells.</p/>(C and D) SYF+c-Src in (C) or HT1080 in (D) cells were seeded for 18 h, followed by serum starvation for 24 h. Cells were pretreated for 1 h with indicated anti-c-Src Ab or IgG as a control, followed by incubation with recombinant TIMP2-His for 2 h. Cell extracts and CMs were collected and analyzed by western blot and pull-down experiments. (C) SYF+c-Src cells were pretreated with anti-c-Src mAb1 (clone 32G6, biotinylated), mAb2 (clone 327), or IgG isotype control (clone DA1E, biotinylated) or were left untreated. Following incubation with recombinant TIMP2-His 6 (rTIMP2-His 6 ), TIMP2-His 6 was pulled-down from CM using Ni-NTA resin. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 and e-Src was determined by immunoblot. GAPDH (cell extracts) was used as loading control (Lys C). (D) HT1080 cells were pretreated with anti-c-Src mAb6 (clone 327537), mAb5 (clone 32G6), or IgG isotype control (clone 20102) or were left untreated. Following incubation with rTIMP2-His 6 , TIMP2-His 6 was pulled down from CM. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 was determined by immunoblot. (E) Schematic representation c-Src SH4/U and SH3 domains. The critical region used as immunogen for generating the polyclonal Ab (aa 84–110) in this study is highlighted in pink. (F) HT1080 cells were pretreated with anti-c-Src pAb (aa 84–110) or IgG isotype control (clone ERP25A) or were left untreated. Following incubation with rTIMP2-His 6 , TIMP2-His 6 was pulled down from CM. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 was determined by immunoblot. (G) Schematic representation of sample preparation for (H). Prostate cancer cells (LNCaP, DU-145, PC-3) were seeded in a 96-well plate for 18 h, followed by the addition (treatment) of the anti-c-Src Ab or IgG isotype control (clone ERP25A). After 72 h, cell proliferation was measured using a WST assay. (H) Proliferation assay on prostate cancer cells treated with the indicated concentration of antibody or IgG was measured by WST assay. The graph shows the percentage of growth normalized to the untreated sample. Data are presented as mean ± SEM derived from two technical replicates. Data presented are a representative result of 3 independent experiments. Paired two-tailed t test was used to assess statistical significance between IgG treatment and anti-c-Src treatment at 50 μg/mL for each cell line (*p < 0.05, **p < 0.01). SE, short exposure; LE, long exposure. See also .
Rabbit Anti Src, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit anti src/product/Cell Signaling Technology Inc
Average 96 stars, based on 1 article reviews
rabbit anti src - by Bioz Stars, 2026-04
96/100 stars
  Buy from Supplier

93
Proteintech csk
FIGURE 5. pDCs lack the activating adaptor molecules but express inhibitory adaptor molecules of SLAM receptors. (A) IFN-a production by RNA-IC–stimulated pDCs after cross-linking of CD319, CD229, or BDCA-2 by plate-bound mAbs. IFN-a levels were determined in 20-h cell culture supernatants by an immunoassay and normalized to the IFN-a production in cultures without plate-bound mAb. The dashed line indicates 100%. Data (mean + SD) are from three donors from two independent experiments. Expression <t>of</t> <t>EAT2</t> and SAP (B) and SHIP-1, SHP-1, SHP- 2, and <t>CSK</t> (C) in cell lysates from isolated pDCs or NK cells from two healthy donors was determined by Western blot. Expression of b-actin was used as control.
Csk, supplied by Proteintech, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/csk/product/Proteintech
Average 93 stars, based on 1 article reviews
csk - by Bioz Stars, 2026-04
93/100 stars
  Buy from Supplier

Image Search Results


(A) Domain structure of human c-Src protein (UniprotKB: P12931) with key regulatory sites illustrated. From the N to the C terminus, domains include the N-term SRC homology SH4 with the U (brown), SH3 (blue), SH2 (orange), KD (SH1; green), and C-term R (red) domains. Domain range is indicated with residue numbers shown below each domain (above for SH3). Regions targeted by the mAbs tested in this study are indicated (black brackets). One asterisk (*) indicates mAbs that inhibit TIMP2 tyrosine phosphorylation and TIMP2 interaction with MMP-2. Two asterisks (**) indicate the mAb6 did not block TIMP2 phosphorylation or its interaction with MMP2 in experiments performed in this figure. (B) Schematic representation of sample preparation and processing for evaluating anti-c-Src Abs in cells.</p/>(C and D) SYF+c-Src in (C) or HT1080 in (D) cells were seeded for 18 h, followed by serum starvation for 24 h. Cells were pretreated for 1 h with indicated anti-c-Src Ab or IgG as a control, followed by incubation with recombinant TIMP2-His for 2 h. Cell extracts and CMs were collected and analyzed by western blot and pull-down experiments. (C) SYF+c-Src cells were pretreated with anti-c-Src mAb1 (clone 32G6, biotinylated), mAb2 (clone 327), or IgG isotype control (clone DA1E, biotinylated) or were left untreated. Following incubation with recombinant TIMP2-His 6 (rTIMP2-His 6 ), TIMP2-His 6 was pulled-down from CM using Ni-NTA resin. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 and e-Src was determined by immunoblot. GAPDH (cell extracts) was used as loading control (Lys C). (D) HT1080 cells were pretreated with anti-c-Src mAb6 (clone 327537), mAb5 (clone 32G6), or IgG isotype control (clone 20102) or were left untreated. Following incubation with rTIMP2-His 6 , TIMP2-His 6 was pulled down from CM. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 was determined by immunoblot. (E) Schematic representation c-Src SH4/U and SH3 domains. The critical region used as immunogen for generating the polyclonal Ab (aa 84–110) in this study is highlighted in pink. (F) HT1080 cells were pretreated with anti-c-Src pAb (aa 84–110) or IgG isotype control (clone ERP25A) or were left untreated. Following incubation with rTIMP2-His 6 , TIMP2-His 6 was pulled down from CM. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 was determined by immunoblot. (G) Schematic representation of sample preparation for (H). Prostate cancer cells (LNCaP, DU-145, PC-3) were seeded in a 96-well plate for 18 h, followed by the addition (treatment) of the anti-c-Src Ab or IgG isotype control (clone ERP25A). After 72 h, cell proliferation was measured using a WST assay. (H) Proliferation assay on prostate cancer cells treated with the indicated concentration of antibody or IgG was measured by WST assay. The graph shows the percentage of growth normalized to the untreated sample. Data are presented as mean ± SEM derived from two technical replicates. Data presented are a representative result of 3 independent experiments. Paired two-tailed t test was used to assess statistical significance between IgG treatment and anti-c-Src treatment at 50 μg/mL for each cell line (*p < 0.05, **p < 0.01). SE, short exposure; LE, long exposure. See also .

Journal: Cell reports

Article Title: PhosY-secretome profiling combined with kinase-substrate interaction screening defines active c-Src-driven extracellular signaling

doi: 10.1016/j.celrep.2023.112539

Figure Lengend Snippet: (A) Domain structure of human c-Src protein (UniprotKB: P12931) with key regulatory sites illustrated. From the N to the C terminus, domains include the N-term SRC homology SH4 with the U (brown), SH3 (blue), SH2 (orange), KD (SH1; green), and C-term R (red) domains. Domain range is indicated with residue numbers shown below each domain (above for SH3). Regions targeted by the mAbs tested in this study are indicated (black brackets). One asterisk (*) indicates mAbs that inhibit TIMP2 tyrosine phosphorylation and TIMP2 interaction with MMP-2. Two asterisks (**) indicate the mAb6 did not block TIMP2 phosphorylation or its interaction with MMP2 in experiments performed in this figure. (B) Schematic representation of sample preparation and processing for evaluating anti-c-Src Abs in cells.

(C and D) SYF+c-Src in (C) or HT1080 in (D) cells were seeded for 18 h, followed by serum starvation for 24 h. Cells were pretreated for 1 h with indicated anti-c-Src Ab or IgG as a control, followed by incubation with recombinant TIMP2-His for 2 h. Cell extracts and CMs were collected and analyzed by western blot and pull-down experiments. (C) SYF+c-Src cells were pretreated with anti-c-Src mAb1 (clone 32G6, biotinylated), mAb2 (clone 327), or IgG isotype control (clone DA1E, biotinylated) or were left untreated. Following incubation with recombinant TIMP2-His 6 (rTIMP2-His 6 ), TIMP2-His 6 was pulled-down from CM using Ni-NTA resin. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 and e-Src was determined by immunoblot. GAPDH (cell extracts) was used as loading control (Lys C). (D) HT1080 cells were pretreated with anti-c-Src mAb6 (clone 327537), mAb5 (clone 32G6), or IgG isotype control (clone 20102) or were left untreated. Following incubation with rTIMP2-His 6 , TIMP2-His 6 was pulled down from CM. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 was determined by immunoblot. (E) Schematic representation c-Src SH4/U and SH3 domains. The critical region used as immunogen for generating the polyclonal Ab (aa 84–110) in this study is highlighted in pink. (F) HT1080 cells were pretreated with anti-c-Src pAb (aa 84–110) or IgG isotype control (clone ERP25A) or were left untreated. Following incubation with rTIMP2-His 6 , TIMP2-His 6 was pulled down from CM. TIMP2 phosphorylation was evaluated using anti-pan-phosY antibody (4G10). Copull-down of MMP2 was determined by immunoblot. (G) Schematic representation of sample preparation for (H). Prostate cancer cells (LNCaP, DU-145, PC-3) were seeded in a 96-well plate for 18 h, followed by the addition (treatment) of the anti-c-Src Ab or IgG isotype control (clone ERP25A). After 72 h, cell proliferation was measured using a WST assay. (H) Proliferation assay on prostate cancer cells treated with the indicated concentration of antibody or IgG was measured by WST assay. The graph shows the percentage of growth normalized to the untreated sample. Data are presented as mean ± SEM derived from two technical replicates. Data presented are a representative result of 3 independent experiments. Paired two-tailed t test was used to assess statistical significance between IgG treatment and anti-c-Src treatment at 50 μg/mL for each cell line (*p < 0.05, **p < 0.01). SE, short exposure; LE, long exposure. See also .

Article Snippet: Anti-c-Src antibodies used for blocking experiments: rabbit anti-Src mAb1 (32G6, biotinylated) (Cell Signaling, #8077), rabbit (DA1E mAb IgG XP Isotype control, biotinylated) (Cell Signaling, #4096), mouse anti-Src mAb2 (Clone 327) (Abcam, #ab16885), rabbit IgG (Abcam, #ab172730), mouse anti-Src mAb3 (L4A1) (Cell Signaling, #2110), rabbit anti-Src mAb4 (36D10) (Cell Signaling, #2109), rabbit anti-Src mAb5 (32G6) (Cell Signaling, #2123), mouse anti-Src mAb6 (clone 327537) (R&D systems, MAB3389), mouse IgG 2A Isotype control (Clone #20102) (R&D systems, MAB003), rabbit pAb (aa 84–110) (custom antibody) (see ).

Techniques: Residue, Phospho-proteomics, Blocking Assay, Sample Prep, Control, Incubation, Recombinant, Western Blot, WST Assay, Proliferation Assay, Concentration Assay, Derivative Assay, Two Tailed Test

Journal: Cell reports

Article Title: PhosY-secretome profiling combined with kinase-substrate interaction screening defines active c-Src-driven extracellular signaling

doi: 10.1016/j.celrep.2023.112539

Figure Lengend Snippet:

Article Snippet: Anti-c-Src antibodies used for blocking experiments: rabbit anti-Src mAb1 (32G6, biotinylated) (Cell Signaling, #8077), rabbit (DA1E mAb IgG XP Isotype control, biotinylated) (Cell Signaling, #4096), mouse anti-Src mAb2 (Clone 327) (Abcam, #ab16885), rabbit IgG (Abcam, #ab172730), mouse anti-Src mAb3 (L4A1) (Cell Signaling, #2110), rabbit anti-Src mAb4 (36D10) (Cell Signaling, #2109), rabbit anti-Src mAb5 (32G6) (Cell Signaling, #2123), mouse anti-Src mAb6 (clone 327537) (R&D systems, MAB3389), mouse IgG 2A Isotype control (Clone #20102) (R&D systems, MAB003), rabbit pAb (aa 84–110) (custom antibody) (see ).

Techniques: Control, Recombinant, Virus, Bradford Assay, Staining, Colorimetric Assay, Software

FIGURE 5. pDCs lack the activating adaptor molecules but express inhibitory adaptor molecules of SLAM receptors. (A) IFN-a production by RNA-IC–stimulated pDCs after cross-linking of CD319, CD229, or BDCA-2 by plate-bound mAbs. IFN-a levels were determined in 20-h cell culture supernatants by an immunoassay and normalized to the IFN-a production in cultures without plate-bound mAb. The dashed line indicates 100%. Data (mean + SD) are from three donors from two independent experiments. Expression of EAT2 and SAP (B) and SHIP-1, SHP-1, SHP- 2, and CSK (C) in cell lysates from isolated pDCs or NK cells from two healthy donors was determined by Western blot. Expression of b-actin was used as control.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Article Title: Systemic lupus erythematosus immune complexes increase the expression of SLAM family members CD319 (CRACC) and CD229 (LY-9) on plasmacytoid dendritic cells and CD319 on CD56(dim) NK cells.

doi: 10.4049/jimmunol.1301022

Figure Lengend Snippet: FIGURE 5. pDCs lack the activating adaptor molecules but express inhibitory adaptor molecules of SLAM receptors. (A) IFN-a production by RNA-IC–stimulated pDCs after cross-linking of CD319, CD229, or BDCA-2 by plate-bound mAbs. IFN-a levels were determined in 20-h cell culture supernatants by an immunoassay and normalized to the IFN-a production in cultures without plate-bound mAb. The dashed line indicates 100%. Data (mean + SD) are from three donors from two independent experiments. Expression of EAT2 and SAP (B) and SHIP-1, SHP-1, SHP- 2, and CSK (C) in cell lysates from isolated pDCs or NK cells from two healthy donors was determined by Western blot. Expression of b-actin was used as control.

Article Snippet: Rabbit polyclonal Abs to Ewing’s sarcoma-activated transcript 2 (EAT2), SHIP-1, SHP-2, CSK (Proteintech Group, Chicago, IL), and a rabbit mAb to SHP-1 (EPR5519; Epitomics, Burlingame, CA), followed by HRP-conjugated goat anti-rabbit IgG (H+L) (Invitrogen), were used to detect the indicated signaling molecules.

Techniques: Cell Culture, Expressing, Isolation, Western Blot, Control